The journey of canakinumab; on- and off-label indications

Beyond Rheumatology 2019; 1 (1): e256
DOI: 10.4081/br.2019.4

  Topic: Rheumatic disease, Therapies     Category:

Marotto Daniela
P. Dettori Hospital, Tempio Pausania (SS), Close
, Batticciotto Alberto
Internal Medicine Department, ASST Settelaghi, Ospedale di Circolo - Fondazione Macchi, Varese, Close
, Ceribelli Angela
ASST Fatebenefratelli-Sacco, Milano, Italy, Close
, Puttini Piercarlo Sarzi
ASST Fatebenefratelli-Sacco, Milano, Italy, Close

Abstract

The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS).
Free PDF Download

To cite this article

Marotto Daniela
P. Dettori Hospital, Tempio Pausania (SS), Close
, Batticciotto Alberto
Internal Medicine Department, ASST Settelaghi, Ospedale di Circolo - Fondazione Macchi, Varese, Close
, Ceribelli Angela
ASST Fatebenefratelli-Sacco, Milano, Italy, Close
, Puttini Piercarlo Sarzi
ASST Fatebenefratelli-Sacco, Milano, Italy, Close
The journey of canakinumab; on- and off-label indications

Beyond Rheumatology 2019; 1 (1): e256
DOI: 10.4081/br.2019.4

Publication History

Published online: 06 May 2019